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Radiation therapy is a part of multidisciplinary management of several childhood cancers. Proton therapy is a new
method of irradiation, which uses protons instead of photons. Proton radiation has been used safely and effectively
for medulloblastoma, primitive neuro-ectodermal tumors, craniopharyngioma, ependymoma, germ cell intracranial
tumors, low-grade glioma, retinoblastoma, rhabdomyosarcoma and other soft tissue sarcomas, Ewing’s sarcoma and
other bone sarcomas. Moreover, other possible applications are emerging, in particular for lymphoma and neuroblastoma.
Although both photon and proton techniques allow similar target volume coverage, the main advantage of proton
radiation therapy is to sparing of intermediate-to-low-dose to healthy tissues. This characteristic could translate into
clinical reduction of side effects, including a lower risk for secondary cancers. The following review presents the state
of the art of proton therapy in the treatment of pediatric malignancies.
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Introduction
Recent therapy progress has improved life expectancy in
pediatric cancer patients, with a 5-year overall survival
(OS) that increased from 39% in 1960 higher than 80%
in 2004 [1]. Radiotherapy (RT) is a fundamental part of
the multimodality treatment applied to achieve local (LC)
and regional control in solid malignancies. Unfortunately,
as survivors live longer, they are at risk of experiencing
late effects from their treatments, including radiation. For
this reason, several combined approaches with chemo-
therapy and surgery have been used to avoid or reduce
RT. Despite of this, many children require radiation and
remain at high risk for developing a multitude of serious
long-term sequelae that result in psychological – social
problems and reduce the quality of life of survivors [2].
Protontherapy (PT) is an external RT modality that
uses protons instead of photons. These charged particles
are accelerated by a cyclotron or synchrotron to reach
high energies. When a proton beam enters the body, it
delivers a constant dose all through the end of the range
where all the remaining energy is deposited within a few* Correspondence: barbara.rombi@apss.tn.it
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unless otherwise stated.millimeters (Bragg peak). The energy and the intensity
of the beam can be varied to obtain a longitudinal trans-
lation (SOBP: spread–out Bragg peak) and cover the en-
tire target volume. In comparison to high-energy photon
treatment, the potential advantages of protons include
distal dose fall off, without dose beyond the end of the
range, reduction of the dose proximal to the target and
reduction of the integral dose (Figure 1). Biologically, pro-
tons have not demonstrated a significant advantage over
photons, with a relative biological effectiveness of protons
of 1.1 compared to photons (1Gy radiobiological equiva-
lent (RBE) = 1Gy × 1.1) [3]. Therefore, tumor control is
predicted to be the same for both techniques, but the
physical properties of protons allow a better sparing of
normal tissues, with the consequent reduction of acute
and late toxicities. This ability is particularly important
during pediatric age, when the growing organs are very
sensitive to radiation effects.
The long life expectancy of survivors and the presence
of genetic mutations that induce malignancies (e.g. the
RB gene mutation in retinoblastoma) are two factors
that cause a significant risk for secondary cancers. The
incidence of radiation-induced tumors expected to be
reduced using PT, but longer follow-ups are needed for
a clinical evidence [4-6].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Patient
Tumor
Figure 1 Simplistic example of depth-dose profiles (PDD) for a 10 cm seated tumor (gray area) within the patient (black circle) using
four-fields photon beams and two-fields proton beams (blue and red lines, respectively). In the bottom right, final PDD due to the sum of
individual photon (blue) and proton (red) beams: protons allow a dose reduction of tissues located before and behind the tumor in comparison
to photons with the same target coverage.
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controversial aspects regarding the clinical use of
proton therapy for pediatric tumors: the limited
number of proton centers which are not geographic-
ally well-distributed in the United States country, the
lack of proton treatment availability in a timely way,
the radiobiological uncertainties of protons might
mean substantial differences in dose-volume histo-
gram for proton and photon and that require a bet-
ter understanding of the radiobiological differences
between the two modalities. He concluded that the
real benefit of proton over photon therapy based on
toxicity reduction would only be realized once pro-
ton therapy data will be available for comparison
with best existing photon outcome data.For a definitive spread of this radiation modality,
the benefits of protons should be evaluated by results
from clinical trials. To date, nearly all-exiting studies
on Children’s Oncology Group (COG) for pediatric
sarcoma including RMS, CNS tumors, Neuroblastoma,
allow proton therapy as radiation treatment modality.
In other countries, PT is not always a recognized
as integral component of clinical trials. Up to now,
although the clinical use of protons has grown, the
proportion of patients treated by protons remains still
small. One of the reasons is that many proton acceler-
ators were not hospital-based, and were unable to
accommodate children that required daily anesthesia
and a proton treatment in a timely manner. Another
aspect is that the allocation of proton treatment
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patients who have proton treatments reimbursed by
insurance are significantly smaller than the population
who should receive PBT [8].
There are also some physical aspects to consider: as
proton technology is still evolving, PT facilities face many
issues regarding the treatment planning and targeting of
protons. Some of them are: to predict dose deposition due
to range uncertainties by modern treatment planning
system, the impact of anatomical changing tissue density
during proton treatment, breathing, uncertainty regarding
RBE [9]. Concern has also been raised about introducing
this expensive technology into medical practice and the
potential impact on the cost of health care. It is worth
noting that while the initial cost of treatment with pro-
tons is higher than that of photon therapy, reduced side
effects resulting an overall cost savings over a lifetime.
Currently, PT is used in the treatment of intracranial
tumors such as ependymoma, medulloblastoma, primitive
neuro-ectodermal tumors (PNET), craniopharyngioma,
germinoma, and low-grade glioma. Regarding extracranial
malignancies, PT is used in case of retinoblastoma,
soft-tissue and bone sarcomas of head and neck and
paraspinal or pelvic regions. The first clinical results of
PT in pediatric oncology are described in the next section.First clinical results
Ependymoma
The current therapeutic approach for localized ependy-
moma is the maximal tumor resection followed by RT.
A dosimetric comparison study [10] between PT and inten-
sity modulated photon radiation therapy (IMRT) showed
a significant dose reduction from radiation of cochlea,
temporal lobes, whole brain and hypothalamus with PT,
while target coverage and dose to organs close to the
target (e.g. brainstem) were similar. An additional sparing
of healthy tissues would be possibly obtainable with inten-
sity modulated PT (IMPT).
Recently, MacDonald et al. [11] reported the outcome
of 70 patients with localized ependymoma (73% infraten-
torial, 27% supratentorial) after total or subtotal resection
followed by PT. At a median follow-up of 46 months,
3-year LC, progression-free survival (PFS) and OS were
83%, 76% and 95%, respectively. Subtotal resection was
significantly associated with worse PFS (54% vs. 88%,
p = 0.001) and OS (90% vs.97%, p = 0.001). Only three
patients had pituitary gland deficiency after PT (growth
hormone deficiency and hypothyroidism) and two patients
had hearing loss. Regarding potential neurocognitive seque-
lae, mean intelligence and adaptive skills after PT were
stable in comparison to the baseline evaluation and did not
changed in different age groups. No cases of secondary
malignancies were identified.Amsbaugh et al. [12] published the clinical results of 8
cases of spinal ependymoma that received PT after local
recurrence (3 cases) or as part of their primary treat-
ment (5 cases). The mean prescribed dose was 51.1 Gy
(RBE). After a mean follow-up of 26 months LC, PFS
and OS were 100%. There were no events of high-grade
toxicity. In comparison to photon therapy, the dose to
the Organs At Risk (OARs) anterior to the vertebral
bodies (i.e. thyroid, heart, small bowel, stomach) was
dramatically reduced.
In conclusion, both dosimetric studies and the first
clinical results suggest that treating ependymoma with
PT can better preserve hearing, neuro-endocrine and
neurocognitive functioning, with similar rates of tumor
control obtained by photon RT.
Craniopharyngioma
RT is usually delivered after limited surgery, at the time
of first diagnosis or at progression, or in exclusive RT
setting [13]. The combined approach with limited surgery
and irradiation reduces the late toxicity of OARs placed in
the chiasmatic or pre-chiasmatic region (i.e. optic chiasm,
hippocampi, hypothalamus and pituitary gland) in com-
parison to radical surgery alone [14]. Merchant et al. [15]
evaluated 3 dimensional imaging and treatment-planning
data including targeted tumor and normal tissues volumes
(entire brain, temporal lobes, cochleas, hypothalamus) of
10 craniopharyngioma patients. Dose-volume data were
compared based on proton and photon treatment modality
using dose-cognitive effects models. Craniopharyngioma
target volume coverage was similar for both treatment
modalities. The differences between proton and photon
dosimetry showed an advantageous sparing of cochleae,
hypothalamus, and normal tissue volumes such as supra-
tentorial brain or temporal lobes, which received less of
the low and intermediate doses. Those differences when
applied to longitudinal models of radiation dose-cognitive
effects resulted in higher IQ scores for craniopharyn-
gioma patients. Figure 2 shows an example of dosimetric
comparison between PT and IMRT plans for craniophar-
yngioma case.
Boehling et al. [16] compared three-dimensional con-
formal PT (3D-CPT), IMPT and IMRT plans of 10
pediatric patients affected by craniopharyngioma. The
target volume coverage was adequate for all modalities
but 3D-CPT and even more IMPT reduced the integral
dose to hippocampus, dentate gyrus, subventricular zone,
brain tissue, cerebellum, brainstem and major cerebral
arteries. Similar results were obtained by Beltran et al. [17]
who compared the same techniques in 14 craniopharyn-
gioma cases. The best conformal technique was IMPT,
which has high sensitivity to target volume changes.
Preliminary clinical results of 16 craniopharyngioma
patients treated with post-operative PT to a total dose of
Figure 2 Axial and sagittal isodose distributions comparing intensity-modulated proton therapy (IMPT) (A) and intensity-modulated
radiotherapy (IMRT) (B). For IMPT plan 3 beam angles were used (1 vertex, 2 symmetric lateral off-axis vertex). For IMRT plan 7 equidistant and
coplanar beams were used. PTV (white), right temporal lobe (yellow), left temporal lobe (green), brainstem (pink), left eye (light blue), right eye
(light green), chiasma (blue) are outlined. The IMPT plan improved sparing of the temporal lobes, orbital structures and both optic nerves. The
integral dose to the brain tissue is decreased with IMPT.
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After a mean follow-up of 62 months, LC and OS were
93% and 80%, respectively, while 75% of patients were
free from late toxicity. The effect of combined surgery
and PT on quality of life was investigated by Laffond
et al. [19] with specific questionnaires administered to
23 families. Depression was registered in 48% of cases,
38% had dysexecutive symptoms and the majority of
families felt “very concerned” by the disease.
In summary, PT showed to be indicated as part of a
multidisciplinary management with the goal to reduce
late sequelae, especially in regards to neurocognitive
functioning.Medulloblastoma and primitive neuro-ectodermal
tumor (PNET)
The standard therapy for children older than 3 years
with medulloblastoma and PNET is maximal safe resec-
tion followed by craniospinal irradiation (CSI) in
addition to posterior fossa or tumor bed boost and
chemotherapy. Patients younger than 3 years, the role of
CSI is still controversial due to important side effects.
Using photon beams, the exit dose from the spinal field
results in irradiation of normal tissues anterior to the
spine i.e. thyroid, heart, lungs, bowel, ovaries, breast and
uterus. PT is better able to spare these organs becauseof the distal dose fall-off in the few millimeters anterior
to the vertebral bodies.
Zhang et al. [20] evaluated the predicted risks of car-
diac toxicities for a 4-year-old boy receiving photon or
proton irradiation CSI for medulloblastoma. They calcu-
lated the relative risk (RR) values using a linear risk
model and the normal tissue complication probability
(NTCP) values using Lyman model. The RR values of
cardiac toxicity were 1.28 with protons versus 8.39 with
photons. The predicted ratios of NTCP (photons/pro-
tons) were much less than unit. They concluded that PT
CSI carried a lower risk of radiogenic cardiac toxicity
compared to photon CSI.
The relative risk of premature ovarian failure (RRPOF)
after cranio-spinal proton radiotherapy was investigated
by Pérez-Andújar and colleagues [21]. They calculated
the equivalent dose delivered to the ovaries of an 11-
year old girl from therapeutic and stray radiation and
then predicted the percentage of ovarian primordial fol-
licles killed by radiation and used this as a measure of
RRPOF among the three radiotherapies. Proton radio-
therapy had a lower RRPOF than conventional photon
radiotherapy or IMRT for all sets of ovaries, regardless
of uncertainties in ovarian location.
Clair et al. [22] generated three plans of a patient affected
by medulloblastoma, while comparing conventional x-rays,
IMRT and PT. PT resulted to be the best technique to
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body and to the cochlea, pituitary, hypothalamus, temporo-
mandibular joint, parotid and pharynx. The dosimetric
advantage of protons over photons RT was documented
by Lin et al. [23] in 9 patients who underwent posterior
fossa irradiation. They reported better sparing of cochlea
and temporal lobe by PT.
Moeller et al. [24] performed pre- and one-year post-PT
audiometric testing in patients treated for medulloblas-
toma who also received platinum-based chemotherapy.
The hearing function of 35 ears was analyzed: the rate of
high-grade ototoxicity was low (5%) and the sensitivity to
low frequencies was preserved. Jimenez et al. [25] reported
the outcomes of 15 very young children (age < 5 years)
treated with upfront chemotherapy and subsequent PT
(local volume for all patients, with the addition of CSI in
11) for medulloblastoma and PNET tumors. At a median
follow-up of 39 months, one patient died for local failure
and one from a non-disease related cause. The remaining
13 out of 15 were alive, free of recurrence. 13% patients
developed grade 3 ototoxicity requiring hearing aids and
20% had grade 2 neuro-endocrinopathy. The IQ index
remained stable during follow-up testing in comparison to
baseline evaluation.
The potential reduction of secondary tumors is well
documented by radiobiological predictive models [4–6],
but clinical data from long term follow-ups are not yet
available. This advantage could translate into new clin-
ical indications, as for example the usefulness of breast
cancer screening in survivors, considered mandatory
after x-ray therapy, that will be unnecessary after CSI
with PT [26].
On the basis of dosimetric studies and early clinical
outcome reports, PT should be strongly considered when
logistically possible for tumors requiring CSI. A recent
debate has risen in the radiation oncology community
[27,28] about PT as being the only ethically appropriate
radiation treatment for medulloblastoma. Hopefully, long-
term follow-up will give the answer.
Germ cell tumor
RT has a fundamental role for these malignancies that
are divided into two histological categories: germinomas
and non-germinomatous germ cells tumors (NGGCT).
For diffuse germinomas and NGGCT RT is delivered as
CSI plus a boost to the initial tumor. For localized
germinomas, the target volume is limited to the whole
ventricular system followed by a boost to the residual
disease [29]. MacDonald et al. [30] compared 3D-CPT
and IMPT plans of 22 germinoma patients with IMRT
obtaining similar target coverage with all three tech-
niques but a substantial sparing of brain tissue with PT.
LC and OS were 100% after a median follow-up of
28 months. The treatment was well tolerated in termsof acute toxicity. Only 4 patients developed late toxicity
(2 hypothyroidism and 2 growth hormone deficiency),
while no neurocognitive or auditory toxicity were detected.
This is currently the only study that shows the early out-
come of patients with germ cell tumors treated with PT.
Although preliminary, the results are interesting from
both the clinical and the dosimetrical point of view not
only for the acute toxicity reduction but also for the
potential advantage on late side effects, such as neuro-
cognitive sequelae due to the lower irradiation of the
temporal lobes.Low-grade glioma
Surgical resection is the main treatment in low-grade
glioma. RT is used particularly for deeply placed tumors,
after incomplete surgery or in the definitive setting after
post-chemotherapy progression [31]. Hug et al. [32]
published the results of 27 patients treated with PT at
doses of 50.4-63 Gy(RBE) after a median follow-up of
3.3 years. PT was used as an adjuvant (44%) or salvage
(56%) intent obtaining LC and OS rate of 87% and 93%
for diencephalic tumors, 71% and 86% for hemispheric
tumors, 60% and 60% for tumors placed in the brain-
stem. All patients with stable disease maintained a good
performance status.
In gliomas of the optic nerves, RT is a treatment option
that should be considered in case of local progression after
surgery or for unresectable tumors. Fuss et al. [33] com-
pared PT plans with 3D-CRT and lateral photon beam
techniques and showed similar conformity and homogen-
eity of dose coverage of the target, but a better sparing of
frontal and temporal lobes, contralateral optic nerve and
pituitary gland.
RT in low-grade gliomas is associated with possible
negative effects in neurocognitive, vascular, visual and
endocrine functioning. PT has shown promising re-
sults in reducing these adverse events thanks to a better
sparing of healthy tissues (i.e. useful vision has been main-
tained in 57% of patients and improved in 29% as reported
by Fuss et al. [33]) while similar local control was
obtained.Soft tissue Sarcoma (STS)
RT is usually part of the multimodal approach of STS
together with chemotherapy and surgery. PT is usually
employed to reduce side effects in cases where the tumor
is in close proximity to critical structures. Timmermann
et al. [34] treated 16 sarcomas located in different sites,
with a total dose of 50.4 - 61.2 Gy(RBE). After a median
follow-up of 18.6 months, two-year PFS and OS were
71.6% and 69.3%, respectively; four patients had local
failure. PT was well tolerated.
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Yock et al. [35] compared 3D photon and proton plans
of seven patients with orbital RMS treated with PT and
evaluated the rate of clinical late effects. PT showed
dosimetric advantage limiting the dose to the brain,
pituitary grand, hypothalamus, temporal lobes and ipsi/
contralateral orbital structures. After a median follow
up of 6.3 years, only one local recurrence had occurred.
Late toxicity was limited, excellent vision was maintained.
Two patients requiring eye drops and none of patients
developed neuroendocrine dysfunction. All patients
had facial dimorphism, 29% mild bone asymmetry and
71% enophthalmos. Kozak et al. [36] compared PT and
IMRT plans of 10 parameningeal RMS patients. PT
reduced dose to orbital structures, optic pathways, whole
brain temporal lobes, brainstem, pituitary, hypothal-
amus, parotid and lacrimal glands with similar target
volume coverage.
Childs et al. [37] published the clinical outcome of 17
patients with parameningeal RMS treated with PT to a
dose ranged between 50.4 and 56 Gy (RBE). With a me-
dian follow-up of 50 months, the 5-year PFS and 5-year
PFS were 59% and 64%, respectively, comparable with
historical photon cohorts. Late effects included failure to
maintain height velocity (n = 3), endocrine deficits (n = 2),
mild facial hypoplasia (n = 7), failure of tooth eruption
(n = 3), dental caries (n = 5) and chronic nasal/sinus
congestion (n = 2). Functional results were better in com-
parison to those observed in photon studies [38,39].
Cotter et al. [40] compared IMRT and PT plans for 7
patients with bladder/prostate RMS. PT led to a significant
decrease in mean dose to bladder, testes, femoral heads,
growth plates and pelvic bones compared to IMRT. After a
median follow-up of 27 months, two recurrences were
observed. Late effects related to PT were very limited: only
one patient had intermittent hematuria.
Ewing sarcoma
In the multimodality management of Ewing sarcoma,
RT is usually used in post-operative setting for patients
with close or positive resection margins after poor response
post-chemo or as a definitive intent for unresectable
tumors. Rombi et al. [41] published initial clinical out-
come of 30 Ewing’s sarcoma patients treated with PT at
a median prescribed dose of 54 Gy(RBE). At a median
follow-up of 38.4 months, 3-year LC, PFS, and OS were
86%, 60%, and 89%, respectively. The PT was very well
tolerated and acute Grade 3 side effects occurred in 6
cases (5 skin desquamation and 1 fatigue). Five patients
(16.7%) who received surgical laminectomy prior to
radiation developed scoliosis/kyphosis (three mild, one
moderate, one severe) and 20% had permanent skin
changes. Four patients developed secondary hemato-
logical tumors (three acute myeloid leukemia and onemyelodysplastic syndrome), potentially due to high doses
of alkylating antineoplastic agents.
In conclusion, PT may be indicated in selected cases
of STS, RMS and Ewing sarcoma, especially in orbital,
parameningeal, paraspinal and pelvic sites to mitigate late
toxicity. Further investigations to evaluate the impact of
PT on bone impairment are needed.Chordoma and Chondrosarcoma
In chordoma and chondrosarcoma RT may be prescribed
in post-operative setting or with exclusive intent. It is usu-
ally delivered at high doses up to 70–76 Gy(RBE). These
tumors are always in close proximity to critical structures,
as brainstem, optic pathways, brain tissue and spinal cord.
Chordomas and chondrosarcomas are historically the
typical pathologies referred to PT facilities. Habrand
et al. [42] evaluated clinical results of 30 children treated
with combined photon and proton RT, with a mean follow
up of 26.5 months. Five year PFS was 100% for chondro-
sarcoma and 77% for chordoma and 5-year OS was 100%
for chondrosarcoma and 81% for chordoma. The acute
tolerance to PT treatment was very good; only one late
severe toxicity case (hearing loss) was registered. Rombi
et al. [43] reported the outcome of 26 patients treated
with PT after a mean follow up of 46 months. In chordoma
cohort, the 5-year LC and 5-year OS were 81% and 89%,
respectively; in chondrosarcoma cohort, the 5-year LC
and 5-year OS were 80% and 75%, respectively. Relatively
few (19%) late complications were described, with no events
of severe grade.
PT is considered a useful RT modality for chordoma
and chondrosarcoma due to the capability to escalate the
dose with acceptable rates of late toxicity.Retinoblastoma
RT is commonly used to preserve the eye and the visual
function in advanced retinoblastomas or in the post-
operative setting for high-risk tumors. Krengli et al. [44]
showed that PT is useful to reduce the integral dose to
healthy tissue, decreasing the risk of bone impairment and
functional sequelae. Also, secondary malignancies could
be reduced particularly in children with hereditary RB
gene mutation, associated with a higher risk of radiation-
induced tumors. Sethi et al. [45] have recently compared
the risk for secondary malignancies in patients with ret-
inoblastoma who were treated with PT (55 patients) and
photon radiotherapy (31 patients). The median follow up
was 6.9 years in proton cohort and 13.1 years in photon
cohort. Ten-year cumulative incidence of radiation-
induced second malignancies was 0% vs.14% (p = 0.015),
respectively.
PT Department at Massachusetts General Hospital of
Boston is treating patients with advanced or high-risk
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regards to secondary-tumor reduction, functional and
cosmetic outcomes [45].
Neuroblastoma
RT is currently part of treatment for high-risk neuro-
blastoma and it is usually delivered on primary tumor
site with limited doses after neoadjuvant chemotherapy
and surgery. The role of PT in neuroblastoma is mainly
investigated for the retroperitoneal site, which accounts
for about the 40% of all cases. Hattangadi et al. [46]
compared dosimetrically 3 different plans (IMRT, 3D-
CPT, and IMPT) of 9 patients. The dosimetric advantage
of 3D-CPT over IMRT was demonstrated in all cases,
while IMPT allowed additional sparing of kidneys, lungs
and heart. In this paper, all cases were treated with
3D-CPT and at a median follow up of 38 months, and
no local failures were detected. Few acute and late side
effects were detected without high-grade toxicity.
Hill Kayser et al. [47] compared 3D-CPT with IMRT
of 13 patients in order to choose the most appropriate
technique in relation to tumor location. For 9 patients
with lateralized disease, PT offered sparing of the
contralateral kidney but in two cases, IMRT improved
overall bilateral renal sparing. They concluded that PT
offered optimal combination between target coverage
and OARs sparing (i.e. bowel, both kidneys, liver, heart,
lungs) in most of the cases (11/13) with 100% of local
control occurred after a mean follow up of 16 months.
Fuji et at. [48] compared 3D-CPT, 3D-CRT and IMRT
plans of 5 cases and obtained similar results regarding
dose sparing. Additionally, by using 3D-CPT the second-
ary cancer risk calculated using a model, which took
in account the rates of cell killing, repopulation and
neutron dose from treatment, was lower in all organs
evaluated (i.e. liver, stomach, small intestine, colon,
bone) except in the pancreas.
The dosimetric evaluations and the first clinical results
of PT in high-risk neuroblastoma are promising. The
potentiality of PT to reduce the dose to organs outside
the target volume could improve the tolerance of a very
aggressive multimodal treatment and decrease the inci-
dence of secondary cancer.
Lymphoma
In recent years, numerous comparative studies have
been conducted to evaluate the potential role of PT in
mediastinal lymphoma. Hoppe et al. [49] evaluated the
plans of stage II-III Hodgkin’s lymphoma (HL) cases with
mediastinal location and they confirmed the advantage of
3D-CPT over conformal RT and IMRT to reduce the dose
to the heart, lungs, esophagus, thyroid and breast. The
same authors [50] published a second article mainly
focused on heart structures, in particular the coronaryarteries, with the potential reduction of late ischemic
damage by PT use. Andolino et al. [51] found that
using 3D-CPT in pediatric female patients with stage
II-HL the dose to the breast was reduced of 80%.
In dosimetric comparison studies of protons and pho-
tons in several tumor types and locations, PT appears
promising in reducing the dose to OARs; it could translate
into reduced incidence of secondary cancer (especially
breast cancer) but clinical evidence are still limited.Conclusions
RT is effective in increasing local control in several
pediatric tumors, but it is often associated with severe
late effects, including secondary tumors. The physical
advantages of protons, which decrease the dose to healthy
tissues, are promising in achieving significant clinical
benefits. Dosimetric comparison studies pointed out the
superiority of protons over photons in several tumor loca-
tions. Clinical data are still limited, but the first evidence
generally confirmed an outcome similar to historic photon
cohort, but better tolerance to PT and few side effects,
that could have positive impact also on the survivors’
quality of life.
Several proton facilities have started their activity during
the last decade and new centers are planned worldwide.
The spread of the PT centers in the near future will make
this technology easily accessible to pediatric patients. With
the increase of follow-up time, the evidence in favor of PT
could become more solid. Specialized teams of radiation
oncologists, medical physicists, anesthesiologists, psychol-
ogists and nurses are needed and new observational
protocols should be designed to investigate the benefits
on late toxicity and quality of life.
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